Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 16/20 | 0.41 |
| ▸ | MMP3 | P08254 | 11/20 | 0.41 |
| ▸ | MMP1 | P03956 | 10/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL351568 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL5087862 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL9800687 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL5092892 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL414762 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL2365613 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL5091440 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL28657602 | 0.98 | CSNK1E (0.52) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Bromide SCHEMBL28853748 | 0.98 | CSNK1E (0.52) | CSNK1EMMP2MMP3MMP1HTR2A | |
| SCHEMBL25287896 | 0.98 | CSNK1E (0.55) | CSNK1EMMP2MMP3MMP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9314849-B2 | Synthesis of nanostructures | NORTH CAROLINA STATE UNIVERSITY (US) | 2016-04-19 | — | — | US | claimed |
| EP-1853605-B1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING SPA (IT) | 2014-09-10 | — | — | EP | claimed |
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2014-06-26 | — | — | US | claimed |
| US-8636977-B2 | Integrin targeted synthetic ligands for diagnostic and therapeutic applications | BRACCO IMAGING S.P.A. (IT) | 2014-01-28 | — | — | US | claimed |
| EP-1383395-B1 | IMPROVED ADDITIVE FOR LIVESTOCK FEEDS | UNIV BRITISH COLUMBIA (CA) | 2011-10-05 | — | — | EP | claimed |
| EP-2283733-A1 | Additive for ruminant feeds, comprising a non-ionic surfactant and an antioxidant agent | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-02-16 | — | — | EP | claimed |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | BRACCO IMAGING S.P.A. (IT) | 2008-12-25 | — | — | US | claimed |
| EP-1853605-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Bracco Imaging, S.P.A. (IT) | 2007-11-14 | — | — | EP | claimed |
| WO-2006095234-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2006-09-14 | — | — | WO | claimed |
| US-20040076659-A1 | Additive for livestock feeds | THE UNIVERSITY OF BRITISH COLUMBIA | 2004-04-22 | — | — | US | claimed |
| EP-0712293-A4 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER EVAN C (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0802788-A1 | NOVEL THERAPEUTIC DELIVERY SYSTEMS | UNGER, Evan C (US) | 1997-10-29 | — | — | EP | claimed |
| US-5585112-A | TEMPERATURE-ACTIVATED FLUORINE-CONTAINING GAS; USEFUL IN ULTRASONIC IMAGING AND DRUG DELIVERY SYSTEMS; FDA ORANGE BOOK LISTED PATENT FOR PERFLUTREN | IMARX PHARMACEUTICAL CORP. (US) | 1996-12-17 | — | — | US | claimed |
| EP-0712293-A1 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER, Evan C (US) | 1996-05-22 | — | — | EP | claimed |
| WO-1994028780-A2 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | claimed |
| WO-1994028874-A1 | NOVEL THERAPEUTIC DELIVERY SYSTEMS | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | claimed |
| EP-0299601-B1 | Method of determining a bacterial concentration and removing non-bacterial cells, and apparatus and reagents for the method | FOSS ELECTRIC HOLDING AS (DK) | 1994-05-11 | — | — | EP | claimed |
| EP-0583468-A1 | PROCESS FOR MAKING PURE PHOSPHATIDYLETHANOLAMINE AND PHOSPHATIDYLMYOINOSITOL | FLARER, S.A. (CH) | 1994-02-23 | — | — | EP | claimed |
| WO-1993016086-A1 | PROCESS FOR MAKING PURE PHOSPHATIDYLETHANOLAMINE AND PHOSPHATIDYLMYOINOSITOL | FLARER S.A. (CH) | 1993-08-19 | — | — | WO | claimed |
| EP-0299601-A1 | Method of determining a bacterial concentration and removing non-bacterial cells, and apparatus and reagents for the method | A/S Foss Electric Holding (DK) | 1989-01-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | ITGA2B, ITGB2, ITGB1 | CSNK1E 1023/4885MMP2 3084/4885MMP3 3451/4885 |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | ITGA2B, ITGB2, ITGB1 | CSNK1E 1023/4885MMP2 3084/4885MMP3 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.